Pharmazz

Pharmazz, Inc. is a clinical-stage pharmaceutical company focused on the discovery, acquisition, development, and commercialization of therapies targeting critical care medicine. The company is developing three novel first-in-class drug products covering multiple critical care indications. Its lead product, Centhaquine, is for the treatment of hypovolemic shock, which urgently needs new therapies. The second compound developed by Pharmazz, Sovateltide, is for the treatment of cerebral ischemic stroke, Alzheimer's disease, and other neurodegenerative diseases. The third compound developed by Pharmazz is for the treatment of diabetic ketoacidosis and the elimination of opioid tolerance.